entertainment -WSS

entertainment

author：leisure time 2025-09-05 06:02:53 - browse：95642

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Timeline: How the deadly wildfires took over Maui day by day

WSS

New oral drug delivery patch is modeled after octopus tentacles

Health insurers' Q3 question: how much care are people getting?

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Experts study whether long Covid risk adds up with each reinfection

Maui wildfire now ranks as the fifth

Patients, digital health players weigh in on FTC's data privacy plan

entertainment

entertainment

hotspot

Sports medicine is finally prioritizing gender equality

CRISPR base editing slashes cholesterol levels in monkeys

Apple is now the first public company to be valued at $3 trillion

Montana youths win climate lawsuit against state for promoting fossil fuels

Drug repurposing or repositioning? The language matters

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

How one medical school became remarkably diverse

What will Novo Nordisk's VC do with its influx of cash?

Wildfire smoke exposes gaps in outdoor worker protections

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

explore

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Bird flu researchers hone in on Finland’s mink farms

Idaho college killings prosecutors challenge defense's grand jury claims

Judge sides with young activists in first

Setback for rare diseases as Taysha Gene Therapies pulls back

Maui wildfire now ranks as the fifth

focus

knowledge

hotspot

focus